Interventional oncology

Cinciprinni PM, McClure JB Smoking cessation recent developments in behavioral and pharmacologic interventions. Oncology 12 249-239, 1998 Clarke PB Nicotinic receptor blockade therapy and smoking cessation. Br J Addict 86 501-503, 1991... 

Department of Radiology, Director, Interventional Oncology, Robert H. Lurie Comprehensive Cancer, 676 N St Clair, Chicago, IL 60611, USA... 

Cianni R, Saltarelli A, Notarianni E et al (2006) Radioembolism (yttrium 90) of hepatic liver metastases preliminary experience. Presented at the World Conference on Interventional Oncology, Cemobbio, Italy... 

The unique aspect of therapy is its minimal toxicity profile and highly effective tumor kill and minimal exposure to normal liver tissue in properly selected patients. These unique characteristics in conjunction with the minimally invasive nature provide an attractive option for patients for whom there are few alternatives. The technical and clinical demands of patient selection, treatment planning, Y administration and clinical follow-up require a dedicated interdisciplinary team willing to work cooperatively to achieve the best result for the patient. The clinical benefit and potential for enhancing quality of life for the patient given this commitment present an exciting research opportunity for the field of interventional oncology. 

In general, tumor ablation can be divided into two main categories. The first one is chemical ablation, the second one is thermal ablation. Additionally, other interventional oncological therapeutic approaches have to he defined, such as the percutaneous dehvery of radioactive seeds and the transcatheter delivery of chemotherapy and chemoemho-lization. 

Chlebowski RT, Col N, Winer EP et al. (2002) American Society of Clinical Oncology Technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 20(15) 3328—3343... 

Visvanathan K et al (2009) American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aro-matase inhibition for breast cancer risk reduction. J Clin Oncol 27 3235-3258... 

In a prospective study to evaluate the impact of a clinical pharmacist in outpatient hematology-oncology clinics, patient charts and profiles were reviewed and patient interviews were conducted to obtain medication historiesWithin a 36-day time period, 211 interventions were documented the majority of these interventions were not related to chemotherapy. The most frequent activities consisted of patient counseling and therapeutic recommendations. Of the problems identified, most were of high and moderate significance and pharmacy interventions yielded positive clinical outcomes. The physician acceptance rate to pharmacists interventions was 94.5%. 

Oncology pharmacists who care for patients in outpatient practice settings typically review patients medication and medical profiles in advance of seeing the patients. This enables them to identify those individuals who are most likely to have medication-related issues or poor symptom management, and who will benefit from the pharmacist s interventions. 

An analysis of self-reported interventions by hematology-oncology pharmacists and staff was also performed to document pharmaceutical care interventions over a period of approximately 8 months at the Walter Reed Army Medical Center.The interventions were analyzed to determine the types of interventions that are most frequently performed, prescribing errors encountered, medication cost avoidance that resulted from the interventions and types of interventions that are associated with medication cost interventions, and intervention acceptance rate by physicians. Interventions were entered into a personal computer and analyzed using CliniTrend Web Support System software (ASHP). Medication cost avoidance was determined if less medication was used, an equally effective but less costly medication was used, or a medication that could not be reused was not prepared. 

Table 6 Summary of interventions reported by hematology-oncology pharmacists at Walter Reed Army Medical Center (October 1, 1995-May 31, 1996)...

Pon, D. Service plans and clinical interventions targeted by the oncology pharmacist. Pharm. Pract. Manage. Q. 1996, 76(1), 18-30. 

Which intervention should the nurse in an oncology physician s office delegate to the unlicensed assistive personnel (UAP) ... 

This book is the result of an intensive and successful collaboration between two leading European centers in interventional radiological oncology which have rapidly acquired extensive experience with this new technique over the past few years. 

By virtue of their training, certification, involvement, and contribution to Y microsphere treatment programs, the disciplines of Radiation Oncology, Nuclear Medicine, and Interventional Radiology are all qualified to use microspheres. They need to fulfill the training and experience requirements set in 10 CFR Part 35.390 or 35.490. 

Embolization therapy has become a major arm of modern interventional therapy. Its applications have become fundamental cores in the multimodality treatment paradigms in trauma, oncology, and endovascular therapy of vascular malformations and aneurysms. Knowledge of different techniques, materials and vascular anatomy and variants is essential to obtain good clinical outcome and minimize complications. 

Cardiac applications of CT Interventional radiology Functional MRI and spectroscopy Interventionid MRI Cardiac MRI Radiation oncology Tissue oigineering" OR of the future Virtual endoscopy Virtual reality Therapeutic drug monitoring Telemedicine ... 

---